Image 1 of 1
Cerebrolysin 60mg
🔬 What Is Cerebrolysin?
Cerebrolysin is a neuropeptide mixture derived from enzymatic breakdown of porcine brain proteins.
It contains low–molecular weight peptides and amino acids that can cross the blood–brain barrier.
It is marketed in several countries (Europe, Asia, Latin America) as a neuroprotective and neurotrophic agent.
Not FDA-approved in the U.S., but widely studied and used off-label.
đź“Ś Clinical Uses (Investigational/Approved in Some Regions)
Cerebrolysin is studied and sometimes prescribed for:
Stroke recovery (ischemic stroke)
Traumatic brain injury (TBI)
Vascular and degenerative dementia (including Alzheimer’s disease)
Cognitive impairment and neurorehabilitation
Parkinson’s disease (supportive)
Multiple sclerosis & neuropathies (experimental)
💉 Dosing – 60 mg Context
Cerebrolysin is usually available in ampoules or vials of 1 ml (5 mg/ml), 5 ml (215 mg/5 ml), 10 ml, and 30 ml.
So, 60 mg is a relatively small dose—most therapeutic protocols use much higher doses:
Typical dose range in studies:
5–30 ml daily IV (which equals 215–1290 mg/day), usually for 10–20 consecutive days.
Maintenance cycles: treatment may be repeated several times a year.
👉 This means that a single 60 mg dose is very low, and may be more common in compounded or research settings, not in standard therapeutic protocols.
⚠️ Safety & Side Effects
Generally considered safe, with decades of clinical use.
Reported side effects:
Headache, dizziness, agitation, sweating
Rare: seizures, confusion (in predisposed patients)
Not recommended in:
Severe epilepsy
Severe kidney impairment
âś… Key Takeaways
Cerebrolysin = neuropeptide mixture with neuroprotective & neurotrophic effects.
60 mg is a very small amount compared to typical clinical doses (hundreds of mg).
Used in research/clinical settings for stroke, dementia, TBI, and neurodegeneration.
Safe overall, but efficacy data is mixed—some studies show benefits, others less conclusive.
🔬 What Is Cerebrolysin?
Cerebrolysin is a neuropeptide mixture derived from enzymatic breakdown of porcine brain proteins.
It contains low–molecular weight peptides and amino acids that can cross the blood–brain barrier.
It is marketed in several countries (Europe, Asia, Latin America) as a neuroprotective and neurotrophic agent.
Not FDA-approved in the U.S., but widely studied and used off-label.
đź“Ś Clinical Uses (Investigational/Approved in Some Regions)
Cerebrolysin is studied and sometimes prescribed for:
Stroke recovery (ischemic stroke)
Traumatic brain injury (TBI)
Vascular and degenerative dementia (including Alzheimer’s disease)
Cognitive impairment and neurorehabilitation
Parkinson’s disease (supportive)
Multiple sclerosis & neuropathies (experimental)
💉 Dosing – 60 mg Context
Cerebrolysin is usually available in ampoules or vials of 1 ml (5 mg/ml), 5 ml (215 mg/5 ml), 10 ml, and 30 ml.
So, 60 mg is a relatively small dose—most therapeutic protocols use much higher doses:
Typical dose range in studies:
5–30 ml daily IV (which equals 215–1290 mg/day), usually for 10–20 consecutive days.
Maintenance cycles: treatment may be repeated several times a year.
👉 This means that a single 60 mg dose is very low, and may be more common in compounded or research settings, not in standard therapeutic protocols.
⚠️ Safety & Side Effects
Generally considered safe, with decades of clinical use.
Reported side effects:
Headache, dizziness, agitation, sweating
Rare: seizures, confusion (in predisposed patients)
Not recommended in:
Severe epilepsy
Severe kidney impairment
âś… Key Takeaways
Cerebrolysin = neuropeptide mixture with neuroprotective & neurotrophic effects.
60 mg is a very small amount compared to typical clinical doses (hundreds of mg).
Used in research/clinical settings for stroke, dementia, TBI, and neurodegeneration.
Safe overall, but efficacy data is mixed—some studies show benefits, others less conclusive.